Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-1178 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1–mediated lung cancer Dong Hoon Shin1, 2*, Jeong Yeon Jo1, 2, Ji-Youn Han1* 1Research institute, 2Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea *These authors contributed equally to this study Corresponding Author: Dong Hoon Shin, Ph.D. Translational Research Branch, Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea. Tel: +82-31-920-2488, E-mail:
[email protected] Corresponding Author: Ji-Youn Han, M.D., Ph.D. Precision Medicine Branch, Research Institute and Hospital, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea. Tel: +82-31-920-1154, E-mail:
[email protected] Running title: Targeted therapy of the SLC3A2-NRG1 fusion gene Disclosure of Potential Conflicts of Interest: All authors declare no potential conflict of interest. 1 Downloaded from mct.aacrjournals.org on September 27, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-1178 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Keywords: SLC3A2-NRG1, NSCLC, ERBB2, ERBB3 Word count: 6549 Total Number of Figure/Tables: 5 2 Downloaded from mct.aacrjournals.org on September 27, 2021.